• Media type: E-Article
  • Title: Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients
  • Contributor: Reinisch, Mattea; Gluz, Oleg; Ataseven, Beyhan; Blohmer, Jens-Uwe; Budner, Marek; Dittmer-Grabowski, Christine; Kohls, Andreas; Krocker, Jutta; Kümmel, Aylin; Hagemann, Friederike; Rüland, Anna; Traut, Alexander; Kümmel, Sherko
  • imprint: S. Karger AG, 2019
  • Published in: Breast Care
  • Language: English
  • DOI: 10.1159/000491792
  • ISSN: 1661-3791; 1661-3805
  • Keywords: Oncology ; Surgery
  • Origination:
  • Footnote:
  • Description: <jats:p>&lt;b&gt;&lt;i&gt;Purpose: &lt;/i&gt;&lt;/b&gt;Although dose-dense (dd) chemotherapy plays a fundamental role in the treatment of breast cancer (BC), a variety of trials have presented divergent survival results. Here, we present data of patients with more than 3 positive axillary lymph nodes (+aLN) receiving dd chemotherapy after a median follow-up period of 12.3 years. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; In the years 1996-2000, 231 patients with invasive BC, ≥pN2a and no evidence of distant metastases were recruited to receive treatment A, i.e. dd 3 × epirubicin (E, 90 mg/m&lt;sup&gt;2&lt;/sup&gt;) + paclitaxel (P, 175 mg/m&lt;sup&gt;2&lt;/sup&gt;) every 2 weeks (q2w) followed by 3 × cyclophosphamide (C)/methotrexate/5-fluorouracil (CMF, 600/40/600 mg/m&lt;sup&gt;2&lt;/sup&gt;, q2w), or treatment B, i.e. 4 × E + C (C, 600 mg/m&lt;sup&gt;2&lt;/sup&gt;) q3w followed by 3 × CMF q3w. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; 113 patients in arm A and 113 patients in arm B were analysed after an updated median follow-up of 12.3 years. The median age was 55 years, with a median number of 6 +aLN, 50.4% had a T2 and 79.2% hormone receptor-positive BC. The disease-free survival (DFS) rate was 53.1% in arm A and 42.5% in arm B (adjusted p = 0.027). The overall survival (OS) rate was 54.9% in arm A and 48.7% in arm B (adjusted p = 0.058). In the multivariable analysis, the tumour burden was a significant predictor for DFS and OS. &lt;b&gt;&lt;i&gt;Conclusion: &lt;/i&gt;&lt;/b&gt;The adjuvant use of dd chemotherapy led to a statistically significant improvement of DFS after a follow-up of 12.3 years.</jats:p>
  • Access State: Open Access